Control CVRF

CVRF

Stage 3

N (%)

Stage 4

N (%)

Stage 5

N (%)

P value

Total

N (%)

Hypertension (n = 75)

Anti-hypertensive use

25 (33.3%)

12 (16%)

38 (50.6%)

0.95

75 (100%)

% on RAAS blockers

17 (36.9%)

7 (15.2%)

22 (47.8%)

0.70

46 (61.3%)

Optimal control

6 (30%)

1 (5%)

13 (65%)

0.19

20 (26.6%)

Dyslipidemia (n = 58)

Statin use n (%)

10 (32.3%)

4 (12.9%)

17 (54.8%)

0.79

31 (53.4%)

Optimal control

9 (56.2%)

1 (6.2%)

6 (37.5%)

0.01

16 (51.6%)

Hyperphosphatemia (n = 11)

phosphate binders use

0 (0.0%)

2 (22.2%)

7 (77.7%)

-

9 (81.8%)

Optimal control

1 (7.7%)

0 (0.0%)

12 (92.3%)

0.15

13 (59.1%)

Anemia (n = 65)

% on treatment

9 (18.3%)

8 (16.3%)

32 (65.3%)

0.12

49 (75.3%)

Optimal control

1 (33.3%)

0 (0.0%)

2 (66.6%)

0.67

3 (6.0%)

Hyperuricemia (n = 58)

% on treatment

14 (33.3%)

6 (14.29%)

22 (52.3%)

0.92

42 (72.4%)

Proteinuria (n = 37)

% on RAAS blockers

6 (25%)

3 (12.5%)

15 (62.5%)

0.088

24 (64.8%)